H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

Denmark-based H. Lundbeck A/S on Monday agreed to acquire Longboard Pharmaceuticals, Inc (NASDAQ:LBPH) for $60.00 per share ...

Pharmaceutical company Lundbeck will acquire Nasdaq-listed Longboard Pharmaceuticals in a $2.6 billion deal, the two ...

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on ...

Fintel reports that on October 15, 2024, HC Wainwright & Co. downgraded their outlook for Longboard Pharmaceuticals (NasdaqGM ...

LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to ...

Analyst Joon Lee of Truist Financial maintained a Buy rating on Longboard Pharmaceuticals (LBPH – Research Report), retaining the price ...

Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker ...

The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals in a deal worth $2.6 billion ...

Lundbeck, una farmacéutica global con sede en Dinamarca, ha acordado comprar Longboard Pharmaceuticals, con sede en La Jolla, ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...